Expects to Record Over 20% Increase in Profit Attributable to Shareholders
HONG KONG, CHINA - Media OutReach - 2 May 2019 - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading companyengaging in the research, development, production, marketing and sale ofgeneric drugs and proprietary medicines, has today announceda positive profit alert. Based on a preliminary reviewon the unaudited consolidated management accounts of the Group for thefinancial year ended 31 March 2019, the Group is expected to record an increaseof over 20% in the consolidated profit attributable to shareholders of the Companyas compared with that for the financial year ended 31 March 2018.
The encouraging results were mainly attributableto a steady growth of generic drug business along with the sales revenuegenerated from newly in-licensed products coupled with an uplifted salesperformance on proprietary medicines. Operatingleverages and financial savingsderived from cost control measures, as well as fair value gain on investmentproperties of the Group are also expected to contribute to the above-mentionedincrease.
Embeddingthe strategies of regional expansion and targeted portfolio enhancement throughin-licensing or products developed in-house, Jacobson Pharma aims to become aleading generic drug and proprietary medicine company in Asia by building acommercially competitive platform in the region.
Backed by a vertically-integrated supplychain and its efficientproduction facilities as well as a robust in-house research and development pipeline, the Group is among the few with the mostextensive sales and distribution coverage in both the private and public sectors in Hong Kong and is poised for abroadened geographic footprint.
Mr. DerekSum, Chairman and Chief Executive Officer of Jacobson Pharma, said, "Theexpected increase in earnings of the Company reflects the effectiveness of ouracross-the-board efforts and demonstrates our capabilities to execute on ourgrowth strategies. From expanding our product portfolios to optimizing the operating leverage across our production facilities as wellas implementing effective cost controls, ourholistic and prudent approach is aimed at facilitating the Group's long-termgrowth and creating value for our shareholders."
About Jacobson Pharma Corporation Limited (雅各臣科研製藥有限公司；Stock Code: 2633)
Jacobson Pharma is the largest generic drug company inHong Kong with over 30% share of the total generic drug market for each yearsince 2012. The Group's proprietary medicines, notably being Po Chai Pills (「保濟丸」), Tong Tai Chung Woodlok Oil (「唐太宗活絡油」), HoChai Kung Tji Thung San (「何濟公止痛退熱散」), Contractubex Scar Gel (「秀碧除疤膏」) Doan's Ointment (「兜安氏藥膏」), Flying Eagle Wood Lok Medicated Oil (「飛鷹活絡油」), Saplingtan (「十靈丹」), Shiling Oil (「十靈油」) and Col-gan Tablet (「傷風克」) have been widely recognized bythe market. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro CapIndex since 1 June 2017. For more details about Jacobson Pharma, please visitthe Group's website: https://www.jacobsonpharma.com